OPEN LETTER

Zero human deaths from dog-mediated rabies by 2030: insights from modelling [version 1; peer review: 2 approved with reservations]

WHO Rabies Modelling Consortium

Abstract

Dog-mediated rabies continues to kill tens of thousands of people every year in low- and middle-income countries despite being an entirely vaccine-preventable disease. WHO and partners have launched a global campaign to reach zero human deaths from dog-mediated rabies by 2030. The primary tools for reaching this target are mass dog vaccination to control and interrupt transmission in domestic dog populations that maintain infection, and appropriate post-exposure prophylaxis (PEP) for rabies-exposed persons to prevent the fatal onset of disease. Models have been developed to assess the feasibility, impact and cost-effectiveness of these measures. From these models, we argue that the 2030 target of zero human rabies deaths is achievable, but will require concerted effort, engagement and investment. A proposed Gavi investment in human rabies vaccines has potential to drive progress towards the 2030 target; however, concomitant investment is needed to scale up mass dog vaccination or this target will be missed. Predicted economic benefits of mass dog vaccination vary according to national PEP provisioning and access to care. Integrated Bite Case Management can enhance surveillance and rationalize PEP use, but needs adapting to and integrating within local health systems and international reporting systems to improve PEP accountability, monitor impacts and support verification of disease freedom. Modelling is required for projecting more realistic and geographically specific timelines for achieving targets, in line with the implementation of interventions. The greatest risk to the ‘Zero by 30’ strategy is the limited long-term cross-sectoral or targeted financing to support countries to deliver and sustain mass dog vaccination.

Keywords

canine rabies, WHO guidelines, post-exposure prophylaxis, validation, verification, mass dog vaccination, zoonosis, surveillance, integrated bite case management

V1 First published: 11 Oct 2019, 3:1564
https://doi.org/10.12688/gatesopenres.13074.1
Latest published: 04 Mar 2020, 3:1564
https://doi.org/10.12688/gatesopenres.13074.2
This article is included in the 2030 goals for neglected tropical diseases collection.

**Corresponding author:** WHO Rabies Modelling Consortium (katie.hampson@glasgow.ac.uk)

**Competing interests:** No competing interests were disclosed.

**Grant information:** The authors acknowledge the support of the Bill and Melinda Gates Foundation through the funding of the NTD Modelling Consortium [OPP1184344]. This work was supported by the Wellcome Trust [207569], the Gavi Learning Agenda, the World Health Organization and the Scottish Funding Council. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2019 WHO Rabies Modelling Consortium. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** WHO Rabies Modelling Consortium. Zero human deaths from dog-mediated rabies by 2030: insights from modelling [version 1; peer review: 2 approved with reservations] Gates Open Research 2019, 3:1564
https://doi.org/10.12688/gatesopenres.13074.1

**First published:** 11 Oct 2019, 3:1564 https://doi.org/10.12688/gatesopenres.13074.1
Disclaimer
The views expressed in this article are those of the author(s). The opinions expressed herein are those of the authors and do not necessarily reflect the views of the World Health Organisation. Publication in Gates Open Research does not imply endorsement by the Gates Foundation.

Background
In over 120 countries around the world, rabies presents a significant threat to human lives and a considerable public health burden. Around 60,000 people die from rabies annually, whilst tens of millions receive costly post-exposure prophylaxis (PEP). The vast majority of these human rabies cases (>99%) are contracted through the bite of a rabid dog. Although fatal following the onset of clinical disease, rabies is entirely preventable. Administration of PEP to rabies exposed persons according to WHO guidelines prevents disease progression and death. However, PEP does not reduce transmission in source domestic dog populations. Mass dog vaccination has been the foundation for the successful elimination of rabies from dogs in North America, Western Europe, Japan and much of Central and South America. In contrast, mass dog vaccination has barely started in most low- and middle-income countries (LMICs) in Africa and Asia, where the disease remains widespread.

Within the context of neglected tropical diseases (NTDs), zoonoses like rabies have been especially neglected. Rabies was not amongst the diseases prioritized in the 2012 London Declaration, endorsed by international, non-government, government and industry partners that committed over US$785 million to the control or elimination of 10 NTDs by 2020. Investment in the 2012 roadmap overlooked zoonoses requiring control of disease in animal or vector reservoirs. However, rabies was listed amongst five Neglected Zoonotic Diseases (NZDs) within the 66th World Health Assembly resolution on NTDs in 2013. The lack of progress on rabies control in Africa and Asia reflects the omission from high-level political advocacy, and the consequences of minimal investment. While rhetoric on the need for a One Health approach - recognizing the interactions between human and animal health and the required intersectoral collaboration - has increased, investment in veterinary public health to deal with endemic zoonoses has been woeful, with veterinary services focused on control of livestock diseases considered valuable for trade.

WHO and partners recently launched a global campaign to address the neglect of rabies, with the aim of achieving zero human deaths from dog-mediated rabies by 2030. Some regions already had targets to interrupt transmission in dogs or reach zero human deaths. The Americas have progressed remarkably: human rabies deaths in the region have declined by >99% from endemic levels, many countries have not reported human deaths from dog-mediated rabies in over a decade (only three countries reported deaths in 2016), and have ostensibly eliminated transmission, with mass dog vaccination discontinued from large areas. Although the Americas had to reset their target dates and are still to verify freedom from dog-mediated rabies, their successes demonstrate what is possible through coordinated mass dog vaccination. The Southeast Asia and Western Pacific regions targets for zero deaths from 2020 have both been reset following limited progress. The Pan-African Rabies Control Network (PARACON) and Association of Southeast Asian Nations (ASEAN) united regional groups across Africa and Southeast Asia, respectively, and are involved in pushing the rabies elimination agenda. However, countries on both continents have yet to demonstrate significant case reductions. Development of a new NTD roadmap for 2030 that includes rabies provides an opportunity to build on successes and reflect on failures to constructively identify obstacles and overcome them.

For rabies, the new roadmap, for the first time, identifies time-bound targets for countries to achieve the long-term goal of zero human rabies deaths, intermediate milestones of 50% mortality reduction and operational prerequisites of 70% mass dog vaccination coverage in high-risk areas. Modelling contributed to policy development in the build up to and subsequent launch of the ‘Zero by 30’ campaign. In this letter, we describe insights from modelling that can inform progress towards the 2030 NTD roadmap and lay out challenges to meeting these targets.

Insights from modelling supporting policy development
The historic lack of investment in NZDs has previously been attributed to an absence of estimates of their burden on society to motivate policy. Human and animal rabies is vastly under-reported in most endemic regions due to a lack of surveillance and reporting capacity, contributing to this cycle of neglect. With this in mind, the Global Alliance for Rabies Control commissioned a study to estimate the global burden of dog-mediated rabies. Building on decision tree models and using updated country data, burden estimates were generated that have been widely cited in advocacy.

Gavi, the Vaccine Alliance, has considered investing in rabies as part of its mission to increase the equitable use of vaccines for children in the world’s poorest countries. The Gavi Learning Agenda on rabies, the outcome of Gavi’s 2013 Vaccine Investment Strategy decision, complemented key policy processes: a Strategic Advisory Group of Experts (SAGE) Working Group reviewed evidence on rabies vaccines and immunoglobulins (July 2016-April 2018) and a review of models on the impact and cost-effectiveness of rabies prevention strategies was undertaken through the Immunization and Vaccines related Implementation Research Advisory Committee (IVIR-AC) in 2017. Both SAGE and IVIR-AC models highlighted that one strategy under consideration, rabies pre-exposure prophylaxis within a routine Expanded Programme on Immunization (EPI), would be expensive and much less cost-effective than direct prevention through PEP. For post-exposure vaccination, intradermal (ID) administration was under all conditions more cost-effective than the widely used intramuscular route. An abridged one-week ID regimen was universally preferred over other regimens recognized by WHO as safe and effective, with potential to reduce costs.
and be more resilient to stockouts during outbreaks. A dose sparing approach to administration (wound infiltration only) of rabies immunoglobulins was also demonstrated to be more cost-effective than previous recommendations. These outcomes considerably simplified recommendations for rabies PEP, which had previously been regarded as unwieldy and complex, and informed the latest WHO position, providing a preferred strategy for improved PEP access under Gavi investment.

Gavi recently announced their support for rabies post-exposure vaccination beginning 2021, subject to funding availability. Models projected that under improved PEP access (Gavi investment), total human rabies vaccine use could remain similar to the status quo across Gavi-eligible countries from 2020–2035 (~73 million), but with millions more (17.4 million) vaccinated by switching to the abridged one-week ID regimen. This would prevent around half a million rabies deaths, making improved PEP access an extremely cost-effective intervention at around $600 per death averted and costing approximately $403.7 million for the 46 currently Gavi-eligible countries. The counterfactual prediction was that although current PEP provision should save around 900,000 lives from 2021–2035, over one million people will otherwise die from rabies. This difference is attributed to addressing the market failure in vaccine supply, with the introduction of free point-of-care access increasing bite victim care seeking and compliance. Models compellingly showed how investing in PEP would be a step to improve equity and commitment to universal health coverage. Nonetheless, they also starkly highlighted that without concomitant investment in dog vaccination, the 2030 target of zero dog-mediated rabies deaths cannot be met. Scaling up dog vaccination according to the Zero by 30 strategy is predicted to avert a further 300,000 deaths in addition to those prevented through PEP. But without dog vaccination, transmission in dogs will become more entrenched and rabies deaths and PEP use are expected to steadily increase in line with population growth.

Vaccinating 70% of dog populations in high-risk areas is a cost-effective and recognized measure to break the rabies transmission cycle. Empirical work shows that achieving 70% coverage is possible and reveals advantages and disadvantages of strategies according to setting. Models identified heterogeneity in vaccination coverage, and specifically areas of low coverage, as a major impediment to progress. Coverage gaps can result from limited resources, poor planning, neglect of particular communities, non-participation by local government units and a lack of monitoring and evaluation. Models further suggest that rabies persists through metapopulation processes. Limited geographical extent of dog vaccinations can therefore leave areas vulnerable to incursions from neighbouring endemic populations.

Another challenge is that even with dog vaccination, PEP costs will likely remain high unless strategies to rationalize PEP are implemented. Integrated Bite Case Management (IBCM) is advocated by WHO, to reduce the costs of PEP once rabies has been controlled. IBCM is a strategy that formally engages the medical and veterinary sectors to assess the risk of exposure to rabies and requirements for PEP. Implementation of IBCM in Haiti, a resource poor endemic setting, improved patient care by identifying and treating those at risk, whilst reducing PEP use by 40–60%. Current PEP access differs dramatically by setting. Chronic shortages occur in the poorest countries where the majority of patients seek care for bites by rabid dogs, whereas access is improved in some middle-income countries and sometimes hundreds of patients are treated for healthy dog bites for every rabies exposure. In endgame settings, where rabies incidence is very low or absent, PEP savings could be much higher. Models with conservative implementation of IBCM, i.e. judicious PEP only after countries reach zero human deaths, predict reduced PEP costs by 20–70%.

Practical implications of the currently proposed goals

To achieve the targets of the 2030 NTD roadmap, considerable progress must be made in the implementation of rabies control and prevention (Table 1). PEP must be distributed in sufficient quantities and equitably to all rabies-exposed people. Gavi support will be crucial and should provide stability and guaranteed funds to maintain production and supply of human vaccines, and catalyse pre-qualification of new suppliers to address ongoing international shortages. In parallel, in most LMICs, mass dog vaccination must be scaled up then maintained at sufficiently high levels through sustained campaigns to interrupt transmission.

The Zero by 30 strategy ambitiously targets the scale up of dog vaccination in >100 countries over the next decade. Given the threat of incursions from neighbouring populations, this coordinated approach should accelerate progress. Coordination of dog vaccination across the Americas provides the model for success, but also illustrates how the poorest states impede progress, i.e. circulation persists where implementation of dog vaccination is weakest, seeding outbreaks elsewhere. Dog vaccination campaigns must be effectively targeted, such that high coverage is maintained locally and nationally. Moreover, delivery methods need tailoring to local contexts, which may require door-to-door vaccinations, capture-vaccinate-release, and supplementary oral vaccination, in addition to central point methods. There is a learning curve to the scaling up of mass dog vaccination. When introduced to communities for the first time, awareness about rabies and trust in dog vaccination may be low, as is the experience and confidence of practitioners, but coverage should increase over consecutive campaigns. This progressive scaling up is recognized by the operational target for countries to achieve 70% vaccination coverage.

Rabies is highly underreported. Validating the targets of zero deaths and 50% mortality reductions will therefore be a challenge. The most recent WHO expert consultation on rabies included, for the first time, chapters with guidance on validation of zero human deaths and verification of dog-mediated rabies freedom. The NTD roadmap highlights timely diagnosis and
accurate assessment of risks combined with strategic use of rapid diagnostic testing to improve surveillance, i.e. key components of IBCM. Indeed, IBCM is identified as a strategy that can sufficiently enhance surveillance for verification\(^9\). Implementation research is, however, urgently needed to provide guidance on operationalization of IBCM across wide-ranging contexts and best practice given anticipated changes over the time horizon until 2030 (Figure 1). Regulatory measures will be needed for quality control of rapid diagnostic tests and affordable production for larger-scale use.

**Risks**

The overwhelming risk to Zero by 30 is the lack of financial support for introduction, implementation and maintenance of mass dog vaccination. Scientific evidence strongly supports the need for sustained high coverage dog vaccination, but most national authorities have not committed sufficient financial resources to support this strategy. Veterinary budgets are typically much smaller than those of health services, and are largely directed towards measures for trade and animal production, not veterinary public health. In most countries that have successfully controlled rabies, the Ministry of Health has led the rabies control programme including financing dog vaccination\(^16\). Unless Ministries of Health recognize dog vaccination as an essential public health intervention for human rabies prevention, the Zero by 2030 target will not be achieved. Instead, continued circulation of rabies in dogs may lead to an over-reliance on PEP. International investment in dog vaccine and technical support has demonstrably catalyzed action and is needed to overcome barriers that otherwise prevent rabies activities being initiated and adopted as routine by LMIC governments.

To support effective mass dog vaccination, canine vaccines must meet potency and safety standards\(^8\). Use of cheap (sub-standard) vaccines is a false economy given the much greater

---

### Table 1. Summary of challenges for reaching the neglected tropical diseases roadmap targets for rabies.

| Current WHO Goal | Technical Feasibility | Requirements | Challenges | Risks | Opportunities |
|------------------|----------------------|--------------|------------|-------|---------------|
| Zero human deaths due to dog-mediated rabies by 2030 and milestones of 50% reductions in human rabies mortality and 70% mass dog vaccination coverage in high-risk areas. Regional targets set for interruption of transmission in dogs in the Americas and zero deaths in ASEAN and SAARC countries. | Technically feasible, but not at current levels of implementation - mass dog vaccination and improved PEP access needs scaling up in most LMICs. | 1. Financial support for dog vaccine procurement and delivery at scale | 1. Funding for dog vaccination | 1. Reliance on PEP to prevent deaths without addressing problem at source, or assessing rabies risk | 1. Leverage Gavi support for PEP to advocate for dog vaccination |
| | | 2. Technical assistance for planning, implementation and monitoring of large-scale dog vaccination (e.g. training and supervision, mobile applications, standardized guidance, integrated reporting systems e.g. adaptation of DHIS2) | 2. Limited veterinary capacity | 2. Use of low quality/unregulated animal (and human) vaccines | 2. Strengthened and harmonized guidance for ‘Zero by 30’ (WHO position paper\(^1\), WHO Technical Report Series, OIE endorsement procedures for dog-mediated rabies national control programmes, OIE Terrestrial Code, the rabies blueprint |
| | | 3. Technical assistance for improving PEP access (ID training, DHIS2 adaptation, EPI integration, PEP management and accountability) | 3. Regulatory issues regarding involvement of (lay) non-veterinarian vaccinators | 3. Requirements for private dog vaccination (paid for by dog owners) | 3. Pilot projects where catalytic funding has developed in-country capacity and a legacy of ongoing action (Tanzania, Philippines, South Africa, Haiti, Namibia, Bangladesh) |
| | | 4. Targeted approaches for human and animal rabies surveillance (e.g. IBCM, use of RDTs) | 4. Weak surveillance with underreporting of human rabies deaths and animal rabies cases | 4. Use of ineffective methods (culling) and ramifications for public trust and expectations of success | 4. Innovative technical assistance (e.g. customized online and onsite training\(^3\) - Institut Pasteur, Rabies Action Center of Excellence - FAO |
| | | 5. Novel approaches for dog vaccine delivery in hard-to-reach populations (e.g. ORV, targeted CVR, community-led approaches) | | 5. Limited technical support for effective surveillance and dog vaccination and its monitoring and evaluation | 5. United Against Rabies Coalition (WHO/OIE/FAO/GARC) and committed partners including animal welfare organizations, the pharmaceutical industry, academics, civil society and local rabies champions |

WHO, World Health Organization; ASEAN, Association of Southeast Asian Nations; SAARC, South Asian Association for Regional Cooperation; PEP, post-exposure prophylaxis; DHIS2, District Health Information System 2; ID, intradermal; LMIC, low- and middle-income country; EPI, Expanded Programme on Immunization; IBCM, integrated bite case management; RDT, rapid diagnostic test; ORV, oral rabies vaccination; CVR, catch-vaccinate-release; OIE, World Organisation for Animal Health; FAO, Food and Agriculture Organization; GARC, Global Alliance for Rabies Control.
costs of vaccine delivery. Furthermore, cheaper, lower quality vaccines can have fatal consequences and dramatically set back elimination programmes\(^4\). Countries in Latin America, with long-standing mass dog vaccination programmes and slow progress towards elimination are notably those using vaccines that do not meet international standards\(^49\). Some countries push for local vaccine production, but quality standards need to be maintained. World Organisation for Animal Health (OIE) vaccine banks are a step towards more affordable procurement of high quality dog vaccines, but budgets need to be committed to dog vaccination for pharmaceuticals to scale up production, and this remains the most enduring challenge\(^50\). Limited regulatory oversight for animal rabies vaccines, which would not be tolerated for human vaccines, is a failure of One Health.

Even in countries with mass dog vaccination, interruptions are common, from financial and logistical challenges to emergencies that divert funds from rabies. Lapses in mass dog vaccination prolong time to elimination\(^28\). Rapid dog population turnover causes coverage to decline and recurrent outbreaks can lead to loss of confidence in vaccination\(^48\). If dog vaccines are considered expensive, governments may instead promote culling, which is visible but ineffective, or dog owners may be charged for vaccination, leading to ineffectual low coverage\(^51\).

A further impediment is that required improvements in surveillance will result in short-term increases in reported cases\(^41\). This can have political implications in rabies-endemic countries and lead to resistance to policies that enhance surveillance. Addressing such perverse incentives is a challenge for elimination programmes, where pressure to reach the end can disincentivize reporting. Even under strong surveillance, dog vaccination must be maintained for years after cases have ceased to be reported to prevent re-emergence\(^53\).

**Future modelling priorities**

Modelling now has an important role to play within the 2030 NTDs roadmap, requiring both new and better data, as well as technical development. In anticipation of Gavi investment and with country specific data, modelling should inform the spatial targeting of PEP. Considerable uncertainty in how rabies control and prevention measures will be implemented makes their impacts difficult to ascertain. Forecasting stepwise progress towards goals in the context of data on the roll out of dog vaccination is therefore a priority, with the need for expedient and realistic dynamical models that can be scaled to specific geographies. The size and connectivity of dog populations determines progress towards elimination. Nonspatial models are inadequate for capturing the low endemic incidence of rabies (<1% dogs infected/year); thus, more complex, data-intensive modelling approaches are required. There is scope for such models to prioritize areas for scale up, to predict the duration over which dog vaccinations will be required to eliminate disease and to assess when dog vaccination can be relaxed. Improved data available from the roll out of mass dog vaccinations and post-vaccination monitoring should inform model development and calibration. Improved data collection methods will be invaluable to populating these models. Transition to electronic data collection can provide timely spatially resolved data to better understand program implementation\(^27\). Programs utilizing mobile applications for large-scale, real-time guidance of vaccination teams has shown effective in both collecting data to improve methodologies and rapidly implementing high-coverage campaigns\(^27\).

Improved dialogue between stakeholders, with a focus on packaging and communicating guidance from models and data, would bring many benefits. Close collaboration between practitioners and modelers to assess the impact and cost-effectiveness of interventions (PEP, dog vaccination, IBCM) could improve implementation, for example, by identifying areas requiring remedial dog vaccination. Models allow the comparison of alternative control strategies, for example, by illustrating the ramifications of low efficacy vaccines or undetected cases from weak surveillance\(^53\). Burden estimates rely heavily on models. Improved surveillance, particularly IBCM, will provide better data to inform and validate dynamic models and burden
Conclusions

WHO’s 3rd report on NTDs in 2013 highlighted four major obstacles for rabies: improving access to PEP, scaling up of mass dog vaccination, maintaining support for elimination once incidence is no longer a major public health threat, and weak surveillance to monitor progress towards targets. These challenges remain, but Gavi investment in human rabies vaccines addresses the first, representing an unprecedented and long overdue recognition of the entirely vaccine-preventable burden of rabies. IBCM can strengthen surveillance over the elimination timeline and prevent PEP costs from escalating, providing a sustainable exit strategy for Gavi and a direct measure of the impact of investment. However, to achieve Zero by 30, Gavi investment needs leveraging to secure country-level and international financing for scaling up mass dog vaccination. Veterinary capacity is limited in most LMICs, with small budgets compared to health, which are not investing in veterinary public health despite the ‘One Health’ rhetoric. Regulatory mechanisms for animal vaccines are much weaker than for human vaccines, even though poor quality dog vaccines are associated with this article.

Data availability

No data are associated with this article.

Acknowledgements

Members of the WHO rabies modelling consortium:
Katie Hampson1, Bernadette Abela-Ridder2, Joel Changalucha3, Sarah Cleaveland, Lea Knopf4, Kennedy Lushasi5, Mary Elizabeth Miranda6, SM Thambi7,8, Kristyna Rysava9, Tenzin Tenzin9, Michael Tildesley1, Ryan Wallace6, Caroline Trotter10

Affiliations:
1. Institute of Biodiversity, Animal Health & Comparative Medicine, University of Glasgow, Glasgow, G12 8QQ, UK
2. Department of the Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland
3. Environmental Health and Ecological Sciences Department, Ifakara Health Institute, Ifakara, Tanzania
4. Field Epidemiology Training Program Alumni Foundation Inc., Quezon City, Philippines
5. Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
6. Paul G Allen School for Global Animal Health, Washington State University, Pullman, Washington, USA
7. The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, Coventry, UK
8. National Centre for Animal Health, Department of Livestock, Ministry of Agriculture & Forests Serbithang, Babesa, Bhutan
9. Centers for Disease Control and Prevention (CDC), Atlanta, USA
10. Department of Veterinary Medicine, University of Cambridge, Cambridge, UK

Corresponding author: Katie Hampson (katie.hampson@glasgow.ac.uk)

We are grateful to members of the WHO Rabies Modelling Consortium and of the Partners for Rabies prevention for supportive collaborations, valuable discussions and feedback. We also thank Andreia Vasconcelos for overlooking the development of this article.

References

1. Hampson K, Couteville L, Lembo T, et al.: Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2013; 7(14): e0007386. Reference Source
2. WHO: Expert Consultation on Rabies, Third Report. (WHO, Geneva). 2018. Reference Source
3. WHO: Rabies vaccines and immunoglobulins: WHO position. Weekly Epidemiological Record. 2018; 93(16): 201–220. Reference Source
4. WHO: Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases. 2015. Reference Source
5. World Health Assembly. World Health Assembly Resolution WHA 66.12:
52. Wallace R, Etheart M, Ludder F, et al.: The Health Impact of Rabies in Haiti and Recent Developments on the Path Toward Elimination, 2010-2015. *Am J Trop Med Hyg*. 2017; 97(4_suppl): 76–83. PubMed Abstract | Publisher Full Text | Free Full Text

53. Townsend SE, Lembo T, Cleaveland S, et al.: Surveillance guidelines for disease elimination: a case study of canine rabies. *Comp Immunol Microbiol Infect Dis*. 2013; 36(3): 249–261. PubMed Abstract | Publisher Full Text | Free Full Text

54. Gibson AD, Mazeri S, Lohr F, et al.: One million dog vaccinations recorded on mHealth innovation used to direct teams in numerous rabies control campaigns. *PLoS One*. 2018; 13(7): e0200942. PubMed Abstract | Publisher Full Text | Free Full Text
Overview:
The letter entitled “Zero human deaths from dog-mediated rabies by 2030: insights from modelling”, in my opinion, has been well written and constructed. In brief, the letter summarises the progress that has been made over the last decade in terms of rabies control. Although well documented in published literature, the letter focuses on the role that modelling has played, ranging from the Burden study to advocate for rabies elimination to the various studies relating to the case being made to Gavi for investment in rabies. The letter also highlights many of the challenges faced in terms of achieving the global goal of Zero by 2030, including the need for improved One Health collaboration and improved access and delivery of veterinary vaccines, supplemented with improved PEP delivery, as a core for success. The letter ends with a fantastic concluding sentence as a call for action.

General comments:
Although well-constructed and suitably developed to cover the majority of key issues, the letter fails to address some key factors that would be critical to success in terms of the Zero by 30 goal. These factors would also benefit from modelling studies and thus are directly applicable to the scope of this letter in the sense of knowledge gaps, future needs and addressing the way forward. Education is a core factor that has been entirely omitted from the manuscript. Without a solid education foundation, community participation and support will not be possible, thus entirely neutralising any investment in veterinary or human vaccines and vaccination. Furthermore, education of health personnel in terms of the newest WHO recommendations and potential Gavi investment based on the ID regimen will be essential. It would be most helpful if this could be adequately addressed in the letter, including potential means in which modelling could contribute to improving education (through analysing impact).

The authors have highlighted some extremely important points that truly make the letter a valuable contribution to scientific literature. Some of these points, however, are separated throughout the letter and thus lessen their impact. Upon initial read, the letter seemed to solely pose problems, with few suggested solutions, but upon closer examination the potential solutions...
or means to address these challenges are in fact mentioned. For example:

- Second paragraph under Future modelling priorities: “Models allow the comparison of alternative control strategies, for example, by illustrating the ramifications of low efficacy vaccines or undetected cases from weak surveillance”. The mention of illustrating the ramifications of undetected cases from weak surveillance through modelling would certainly be critical. However, this point could be strengthened by relating it back to the following sentence: “A further impediment is that required improvements in surveillance will result in short-term increases in reported cases” in the last paragraph of the “Risks” section.

**Minor comments:**

1. Abstract: “Modelling is required for projecting more realistic and geographically specific timelines for achieving targets, in line with the implementation of interventions.” – Are the projection of timelines based on modelling required considering a relatively short time frame to reach the achievable goal of Zero by 30? Based on the content of the rest of the letter, there are other models that should rather be prioritised. This need is reiterated again powerfully in the concluding sentence of the letter.

2. Background, third paragraph: “The Southeast Asia and Western Pacific regions targets for zero deaths from 2020”. Please amend “regions” to “region’s” (possessive).

3. Background, fourth paragraph: “For rabies, the new roadmap, for the first time, identifies time-bound targets for countries…”. Please can you refer to the name of the roadmap for clarity and provide a reference.

4. Figure 1: Please reference this figure

5. Future modelling priorities, first paragraph: “In anticipation of Gavi investment and with country specific data, modelling should inform the spatial targeting of PEP.” This sentence is unclear as to what the goal would be and can be interpreted to be in direct contradiction to the following sentence “PEP must be distributed in sufficient quantities and equitably to all rabies-exposed people” (Practical implications of the currently proposed goals, first paragraph)

6. Risks, third paragraph: “If dog vaccines are considered expensive, governments may instead promote culling...”. Are dog vaccines themselves considered expensive in rabies endemic countries, or is this rather due to the cost of delivery? Furthermore, the related logistical efforts needed (typically due to poor planning) for dog vaccination often make culling seem a more appropriate and feasible short-term answer. I suggest rephrasing to “If effort and cost related to dog vaccination seem excessive, governments...”

7. Conclusions: “Veterinary capacity is limited in most LMICs, with small budgets compared to health, which are not investing in veterinary public health despite the ‘One Health’ rhetoric.” – this sentence is ambiguous. Please rephrase.

8. Conclusions: “The intermediate target of 70% coverage is the critical directly measurable indicator” – Although 70% coverage is a directly measurable indicator, it remains challenging to measure based on the lack of data or estimates for dog populations in different geographic locations, especially considering both owned and unowned/free-
roaming dogs should be included. Including a more accurate and feasible means to estimating dog populations in future modelling priorities would certainly be something worth consideration and discussion.

9. References: Reference 14 is incomplete.

**Is the rationale for the Open Letter provided in sufficient detail?**
Yes

**Does the article adequately reference differing views and opinions?**
Yes

**Are all factual statements correct, and are statements and arguments made adequately supported by citations?**
Yes

**Is the Open Letter written in accessible language?**
Yes

**Where applicable, are recommendations and next steps explained clearly for others to follow?**
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Rabies Epidemiology, public health and surveillance

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 24 Feb 2020

Katie Hampson,

We are grateful for the positive review. We agree entirely with the point on the importance of education and awareness raising, which was also highlighted by the first reviewer. We have edited the manuscript to emphasise this need and indicate how modelling and analysis could be used to measure the impact of such efforts.

We are also grateful for the reviewer pointing out some slightly disjointed points in our manuscript. We have tried to better indicate potential solutions to the challenges that we raise, and have restructured in places or directed the reader to where solutions are discussed.

We have also tried to address each of the minor points raised by the reviewer, including revising the text to improve clarity (in the abstract, the Future modelling priorities section, the risks section and conclusion), correcting punctuation, referring to figures clearly, correcting references and
Florence Cliquet
Nancy Laboratory for Rabies and Wildlife, French Agency for Food, Environmental and Occupational Health & Safety (ANSES), Malzéville, France

The paper Zero human deaths from dog-mediated rabies by 2030: insights from modelling is a short review of the global state of the art of the Zero by 30 strategy. The paper is well constructed, detailing the background of the initiative, the main challenges and the global results achieved so far. The priorities for future modelling are described.

The title of the manuscript is not completely appropriate, as most information given in the paper is not linked to the modelling approach. All the challenges and the problems described have been identified since a long time and will not be solved by a modelling approach.

In this quite recent initiative, the veterinary public authorities are in charge of the most difficult task, i.e. mass vaccination of dogs, mainly because of a lack of organisation and infrastructure in many countries because rabies and dogs are not a political priority. Vaccinating every year 70% of the dog population, even with money, is highly difficult to implement in a short time (in Americas, it required more than 30 years), as it mainly requires planning, coordination, organisation and evaluation of the implemented actions during all the year and in local settings. The methodology with the different techniques to reach dogs as well as gaps are known and published in many papers; it needs also sustainability for a long time (this notion of sustainability should be mentioned in the paragraph starting by Vaccinating 70% of dog....). So the paper is too severe when concluding on the actions undertaken by the veterinary authorities that are judged as insufficient (....veterinary services focused on .....). The paper should more reflect the difficulty of this task and should also insist on the fact that the One Health approach should be elaborated concretely at the local basis, even on limited areas at the start, associating the people of MoH and MoA to work together, at the same time, particularly for IBCM. The One Health approach is precisely aimed to create concrete collaborations within the different stakeholders to enhance control and prevention.

The notions of education and awareness of the population are not sufficiently stressed in the paper, they are essential. Rabies surveillance and control are more efficient when the population participates closely with the veterinary services, particularly for reporting suspect cases.
(surveillance) and for presenting animals during mass parenteral vaccination campaigns. The paper of Ripani (Ripani A., Mérot J., Bouguedour R., Zrelli M. Review of rabies situation and control in the North African Region with a focus on Tunisia) should be added to the reference list, showing clearly the importance of awareness of the population.

The sentence Dog vaccination campaigns must be.... should be changed for Dog vaccination campaigns should be effectively targeted and implemented every year, such that high coverage....

OVD is an expensive method rhetorically miraculous, however the drawbacks are numerous as soon as we test it in the field in local conditions; this method is to be used for countries close to elimination, which are already engaged in efficient mass parenteral vaccination with good results, and which have still rabies pockets in defined areas. Therefore, the following sentence has to be moderated for: “Moreover, delivery methods need tailoring to local contexts, which may require door-to-door and central point method vaccinations, capture-vaccinate-release, and possibly supplementary oral vaccination in well designed areas. Please insert in this sentence a recent review on OVD (Cliquet F., Guiot A.L., Aubert M., Robardet E., Rupprecht C.E., Meslin F.X. - Oral vaccination of dogs: a well-studied and undervalued tool for achieving human and dog rabies elimination).

The reference 44 is not cited in the text.

A reference (Taylor E., Banyard A.C., Bourhy H., Cliquet F., Ertl H., Fehlner-Gardiner C., Horton D.L., Mani R.S., Müller T., Rupprecht C.E., Schnell M.J., Del Rio Vilas V., Fooks A.R. - Avoiding preventable deaths: The scourge of counterfeit rabies vaccines) should be added for the sentence “Use of cheap (substandard) vaccines is a false......“.

References
1. Ripani A, Mérot J, Bouguedour R, Zrelli M: Review of rabies situation and control in the North African region with a focus on Tunisia. Rev Sci Tech. 2017; 36 (3): 831-838 PubMed Abstract | Publisher Full Text
2. Cliquet F, Guiot A, Aubert M, Robardet E, et al.: Oral vaccination of dogs: a well-studied and undervalued tool for achieving human and dog rabies elimination. Veterinary Research. 2018; 49 (1). Publisher Full Text
3. Taylor E, Banyard AC, Bourhy H, Cliquet F, et al.: Avoiding preventable deaths: The scourge of counterfeit rabies vaccines. Vaccine. 2019; 37 (17): 2285-2287 PubMed Abstract | Publisher Full Text

Is the rationale for the Open Letter provided in sufficient detail?
Yes

Does the article adequately reference differing views and opinions?
Yes

Are all factual statements correct, and are statements and arguments made adequately supported by citations?
Partly

Is the Open Letter written in accessible language?
Yes

Where applicable, are recommendations and next steps explained clearly for others to follow?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Rabies immunology, vaccinology and epidemiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 24 Feb 2020**

**Katie Hampson,**

We are grateful for the positive review and understand the comment that many of the problems raised in the manuscript will not be solved by a modelling approach. Our intention was to highlight those issues that make modelling challenging rather than indicating that modelling would solve them. In our revision we have tried to be clearer on this.

We have highlighted the need for sustainability in the paragraph suggested and have revised the text to indicate the importance of One Health and intersectoral collaboration to achieve these ambitious goals.

We are grateful for the reviewer highlighting the three highly relevant references, which we now include together with appropriate edits to reflect the reviewer’s suggestions.

We also corrected the sentence on dog vaccination as suggested. We note that reference 44 is cited in Table 1. We also now cite the reference in the main text.

**Competing Interests:** No competing interests were disclosed.